Document is current
Any future updates will be listed below
-
Authors
Akhtar, Mohd Waseem
Sanz-Blasco, Sara
Dolatabadi, Nima
Parker, James
Chon, Kevin
Lee, Michelle S.
Soussou, Walid
McKercher, Scott R.
Ambasudhan, Rajesh
Nakamura, Tomohiro
Lipton, Stuart A.
- License Information
-
More Information
Article History
Received: 19 May 2015
Accepted: 19 November 2015
First Online: 8 January 2016
Competing interests
: S.A.L. is the named inventor on worldwide patents for memantine (Namenda®) for the treatment of neurodegenerative diseases. Following Harvard University guidelines, he participates in a royalty sharing agreement with his former institution Harvard Medical School/Boston Children’s Hospital for the licensing of these patents to Forest Laboratories (now Actavis, Inc.). He is also a Scientific Founder of Adamas Pharmaceuticals, Inc., which has agreements with Forest Laboratories/Actavis for the co-development and marketing of long-lasting formulations of memantine. The remaining authors declare competing interests.
